Nxera Pharma Co., Ltd. (4565) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sumitomo Pharma Co., Ltd.

Nippon Shinyaku Co., Ltd.

Towa Pharmaceutical Co., Ltd.

Mochida Pharmaceutical Co., Ltd.

Tsumura & Co.

Hisamitsu Pharmaceutical Co., Inc.

Suzuken Co., Ltd.

JCR Pharmaceuticals Co., Ltd.

SAWAI GROUP HOLDINGS Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Nxera Pharma Co., Ltd.

Why is Nxera Pharma Co., Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.54%

The company has declared negative results in Jan 70 after 3 consecutive negative quarters

OPERATING CASH FLOW(Y) Lowest at JPY -8,796 MM
PRE-TAX PROFIT(Q) At JPY -1,566 MM has Fallen at -332.6%
NET PROFIT(Q) At JPY -2,377 MM has Fallen at -67.16%

Risky - Negative Operating Profits

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -23.66%, its profits have risen by 73.4%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -23.66% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Nxera Pharma Co., Ltd. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Nxera Pharma Co., Ltd.

-23.66%

77.22

45.66%

Japan Nikkei 225

28.54%

1.11

25.75%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

31.83%

EBIT Growth (5y)

-252.78%

EBIT to Interest (avg)

-1.07

Debt to EBITDA (avg)

Net Debt to Equity (avg)

0.43

Sales to Capital Employed (avg)

0.17

Tax Ratio

42.39%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

7.52%

ROE (avg)

1.54%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.27

EV to EBIT

-20.00

EV to EBITDA

-70.53

EV to Capital Employed

1.19

EV to Sales

3.69

PEG Ratio

Dividend Yield

ROCE (Latest)

-5.96%

ROE (Latest)

-3.45%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET SALES(HY)

At JPY 15,094 MM has Grown at 18.66%

NET PROFIT(HY)

Higher at JPY -3,137 MM

RAW MATERIAL COST(Y)

Fallen by -32.23% (YoY

-21What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at JPY -8,796 MM

PRE-TAX PROFIT(Q)

At JPY -1,566 MM has Fallen at -332.6%

NET PROFIT(Q)

At JPY -2,377 MM has Fallen at -67.16%

DEBT-EQUITY RATIO (HY)

Highest at 48.17 %

INTEREST(Q)

Highest at JPY 1,258 MM

EPS(Q)

Lowest at JPY -26.38

Here's what is working for Nxera Pharma Co., Ltd.

Net Sales

At JPY 15,094 MM has Grown at 18.66%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Raw Material Cost

Fallen by -32.23% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at JPY 1,095 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (JPY MM)

Here's what is not working for Nxera Pharma Co., Ltd.

Pre-Tax Profit

At JPY -1,566 MM has Fallen at -332.6%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit

At JPY -2,377 MM has Fallen at -67.16%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (JPY MM)

Operating Cash Flow

Lowest at JPY -8,796 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (JPY MM)

Interest

At JPY 1,258 MM has Grown at 405.22%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest

Highest at JPY 1,258 MM

in the last five periods and Increased by 405.22% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Profit

Lowest at JPY -2,377 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

EPS

Lowest at JPY -26.38

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (JPY)

Debt-Equity Ratio

Highest at 48.17 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio